Curves were generated by modeling RT start time using restricted cubic splines with 4 knots, located at the 5th, 35th, 65th, and 95th percentiles of relative start times for each risk subgroup.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dee EC, Mahal BA, Arega MA, et al. Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncol. 2020;6(10):1630–1632. doi:10.1001/jamaoncol.2020.3545
The coronavirus disease 2019 (COVID-19) pandemic poses challenges for patients with localized prostate cancer (PC) who require radiotherapy (RT), often administered with 6 to 36 months of androgen deprivation therapy (ADT). Daily hospital trips for RT create many possible points of COVID-19 transmission, and patients with cancer are at high risk of COVID-19 mortality.1 Therefore, an important option for patients being treated with RT and ADT is delayed RT initiation. Two prior randomized trials examined the relative timing of ADT and RT.2,3 Malone et al2 and the NRG Oncology/Radiation Therapy Oncology Group 9413 trial (NRG/RTOG 9413)3 showed no difference in overall survival (OS) when RT was started after ADT initiation vs when RT was started before or concurrently with ADT. However, neither trial had a noninferiority design, they were not powered for OS, and the enrolled patients may have been younger and healthier than the average real-world patient, limiting generalizability. Therefore, we used data from a large, contemporary database of patients with clinically significant localized PC to examine the association between OS and RT timing in patients receiving RT and ADT.
Using the patient-deidentified National Cancer Database,4 we identified men diagnosed from 2004 to 2014 with PC that met National Comprehensive Cancer Network criteria for unfavorable intermediate-risk PC (Gleason score 4 + 3 = 7 [primary Gleason pattern 4 with secondary pattern 3], or >1 of the following: Gleason score of 7, prostate-specific antigen [PSA] level of 10-20 ng/mL, clinical stage T2b-T2c) (to convert PSA concentration to micrograms per liter, multiply by 1.0) or high-risk or very high-risk PC (Gleason score of 8-10, PSA level >20 ng/mL, clinical stage T3-T4)5 and whose cancer was managed with external beam RT and ADT. The Dana-Farber/Harvard Cancer Center institutional review board deemed this study exempt from the need for review board approval and patient informed consent because deidentified data were used.
To approximate groups from prior trials,2,3 start times were categorized as follows: RT 0 to 60 days before ADT initiation (reference group) (n = 3572), RT 1 to 60 days after ADT initiation (n = 23 207), RT 61 to 120 days after ADT initiation (n = 30 285), and RT 121 to 180 days after ADT initiation (n = 6794). Multivariable Cox regression compared 10-year OS, hazard ratios (HRs), and 95% CIs across the groups. The multivariable Cox survival analysis was adjusted for the following clinical and sociodemographic characteristics: Gleason score, PSA, T stage, race, age, year of diagnosis, facility type, region, county type (rural or urban), distance traveled to the treatment facility, Charlson-Deyo comorbidity score, insurance status, and zip code–wide median household income. A continuous, nonlinear relationship between RT start time and OS was assessed using a restricted cubic spline transformation with 4 knots followed by plotting of the relative HR and 95% confidence bands (reference category: RT started 60 days before ADT).6
Of the 63 858 men included in this study, 79.2% were White individuals, 16.8% were Black individuals, 2.2% were Asian American individuals, and 0.2% were Native American individuals. An additional 1.6% of individuals did not identify as any of the above race/ethnicity categories and were classified as other. The mean (SD) age was 69.9 (7.9) years. The Table shows baseline characteristics. Among men with unfavorable intermediate-risk PC (4220 total deaths), the 10-year OS for men who initiated RT 0 to 60 days before ADT initiation was 59.2%, RT 1 to 60 days after ADT initiation was 57.9%, RT 61 to 120 days after ADT initiation was 62.3%, and RT 121 to 180 days after ADT initiation was 58.9%. No OS difference was found for groups receiving later RT compared with those receiving RT 0 to 60 days before ADT initiation (1-60 days after: HR, 1.03; 95% CI, 0.90-1.19; P = .64; 61-120 days after: HR, 0.95; 95% CI, 0.82-1.08; P = .42; and 121-180 days after: HR, 0.99; 95% CI, 0.85-1.16; P = .90).
Among men with high-risk or very high-risk PC (10 959 total deaths), the 10-year OS for men who initiated RT 0 to 60 days before ADT initiation was 58.9%, RT 1 to 60 days after ADT initiation was 51.7%, RT 61 to 120 days after ADT initiation was 54.8%, and RT 121 to 180 days after ADT initiation was 52.4%. No OS difference was found for groups receiving later RT compared with RT before ADT initiation (1-60 days after: HR, 1.07; 95% CI, 0.98-1.17; P = .12; 61-120 days after: HR, 1.04; 95% CI, 0.96-1.14; P = .36; and 121-180 days after: HR, 1.07; 95% CI, 0.97-1.18; P = .17).
Date of RT initiation, modeled continuously and nonlinearly, was not associated with OS (Figure; 95% confidence bands include HR = 1).
Based on analysis of a large database of patients with unfavorable intermediate-risk, high-risk, or very high-risk PC, later RT initiation up to 6 months after ADT initiation was not associated with worse OS compared with initiating RT before ADT. These results validate the findings of 2 prior randomized trials2,3 and possibly justify the delay of prostate RT for patients currently receiving ADT until COVID-19 infection rates in the community and hospitals are lower. Limitations of this study included the short follow-up period, retrospective design, lack of information about ADT duration, and possible data entry errors in the database. Nonetheless, if COVID-19 outbreaks continue to occur sporadically during the coming months to years, these data could allow future flexibility about the timing of RT initiation.
Accepted for Publication: June 12, 2020.
Corresponding Author: Vinayak Muralidhar, MD, MSc, Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (email@example.com).
Published Online: August 13, 2020. doi:10.1001/jamaoncol.2020.3545
Author Contributions: Mr Dee and Dr Muralidhar had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Dee, Muralidhar.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Dee, Arega, Muralidhar.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Dee, Mahal, Arega, Muralidhar.
Administrative, technical, or material support: Arega, D’Amico.
Supervision: Mouw, Nguyen, Muralidhar.
Conflict of Interest Disclosures: Dr Mahal reported receiving grants from the Prostate Cancer Foundation, American Society for Radiation Oncology, and US Department of Defense outside the submitted work. Mr Arega reported receiving personal fees from Sarepta Therapeutics outside the submitted work. Dr Nguyen reported receiving grants and personal fees from Bayer, Janssen, and Astellas and personal fees from Boston Scientific, Dendreon, Ferring, COTA, Blue Earth Diagnostics, and Augmenix outside the submitted work. Dr Muralidhar reported receiving a grant from the Conquer Cancer Foundation outside the submitted work. No other disclosures were reported.
Funding/Support: This study was funded by grant R01-CA240582 from the National Institutes of Health (Dr Nguyen).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Marie Gabrielle Dee, BA, for assistance with proofreading the manuscript and Paul J. Catalano, ScD, Department of Biostatistics, Harvard T.H. Chan School of Public Health, for biostatistical assistance. Neither contributor received financial compensation.
Create a personal account or sign in to: